Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which anti-thyroid drug?

D S Cooper

    The American Journal of Medicine
    |June 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Methimazole is recommended for routine Graves' disease treatment due to its cost-effectiveness and lower toxicity. Propylthiouracil remains crucial for specific cases like thyroid storm and during pregnancy or lactation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The impact of age and gender on papillary thyroid cancer survival.

    The Journal of clinical endocrinology and metabolism·2012
    Same author

    A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

    The Journal of clinical endocrinology and metabolism·2003
    Same author

    Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration.

    The Journal of clinical endocrinology and metabolism·2001
    Same author

    Diabetes mellitus--a call for papers.

    JAMA·2001
    Same author

    Langerhans cell histiocytosis of the thyroid: a report of two cases and review of the literature.

    Thyroid : official journal of the American Thyroid Association·2001
    Same author

    Clinical practice. Subclinical hypothyroidism.

    The New England journal of medicine·2001
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric Panniculitis.

    The American journal of medicine·2026
    Same journal

    Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

    The American journal of medicine·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Diffuse toxic goiter, or Graves' disease, is commonly treated with anti-thyroid drugs.
    • Propylthiouracil (PTU) is frequently prescribed over methimazole (MMI) in the United States.

    Purpose of the Study:

    • To compare the efficacy and safety of methimazole and propylthiouracil for Graves' disease management.
    • To provide guidance on the optimal selection of anti-thyroid medication based on patient-specific factors.

    Main Methods:

    • Comparative analysis of drug properties, including dosing, cost, and toxicity profiles.
    • Review of pharmacologic factors influencing drug choice in specific clinical scenarios.

    Main Results:

    • Methimazole offers advantages for routine Graves' disease treatment: single daily dosing, lower cost, and reduced major toxicity at low doses.

    Related Experiment Videos

  • Propylthiouracil is indicated for specific situations, including thyroid storm and use in pregnant or lactating women, due to distinct pharmacologic properties.

    • Conclusions:

    • Methimazole should be the preferred agent for the routine management of Graves' disease when anti-thyroid therapy is chosen.
    • Propylthiouracil remains essential for specific patient populations and acute conditions, necessitating careful consideration of individual patient needs.